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Introduction
Systemic lupus erythematosus (SLE) is a complex, multi-
organ, autoimmune disease. It is characterized by an 
autoimmune response directed against multiple nuclear 
components, of which the nucleosome is the major 
autoantigen [1]. SLE autoantigens cluster in blebs formed 
at the surface of apoptotic cells [2]. Th e exact etiology of 
SLE is still unclear, although insuﬃ  cient clearance of 
apoptotic material and/or aberrant apoptosis, in 
combination with a susceptible genetic background, have 
been suggested to be involved in SLE development and 
progression [3,4]. Multiple SLE-associated autoreactive 
antibodies, which are found in both SLE patients and 
lupus mouse models, recognize apoptosis-induced 
modiﬁ cations of nuclear autoantigens. It has been 
demonstrated that the pathogenic autoantibodies result 
from CD4+ T cell-dependent immune responses. Activation 
of the autoimmune T helper (Th ) cells requires immuno-
genic antigen presentation by dendritic cells (DCs) [5]. 
Here, we provide an overview of the role of DCs and their 
response to apoptotic material in the pathogenesis of SLE.
Dendritic cells
At the interface of innate and adaptive immunity, DCs 
play a pivotal role in the regulation of immune responses. 
DCs are distributed throughout the body for optimal 
antigen capture and, as the most potent antigen 
presenting cells, they are well suited to activate (naïve) 
T cells. On the other hand, immature DCs can promote 
epitope-speciﬁ c peripheral tolerance by presenting 
antigens acquired from dying cells without co-
stimulation of T cells. Th is results in anergy or deletion of 
self-reactive T  cells and the development of regulatory 
T  cells (Tregs) [5]. Depletion of DCs in mice results in 
breaking of self-tolerance of CD4 T cells and induction of 
spontaneous autoimmunity [6], reﬂ ecting the importance 
of DCs in peripheral tolerance. On the other hand, 
inhibition of apoptosis in mouse DCs by Bim-deﬁ cieny 
leads to overstimulation of T  cells by DCs. Th is over-
activation of T  cells then results in breakage of self-
tolerance and induction of autoimmunity in mice [7], 
indicating the ability of DCs to induce autoimmune 
responses. When an antigen is perceived by DCs as being 
harmful, T cells recognizing the antigen will be activated. 
In order to activate T cells, DCs undergo a process called 
maturation, migrate to secondary lymphoid organs, and 
present antigens in an immunogenic context to T  cells. 
During the process of maturation, DCs are transformed 
from predominant antigen-capturing cells towards 
antigen-presenting cells. DCs thereby increase the 
expression of antigen-loaded major histocompatibility 
complex (MHC) molecules, upregulate the expression of 
co-stimulatory molecules (that is, CD86, CD40) and 
secrete pro-inﬂ ammatory cytokines and chemokines, 
such as IL-6 and TNF-α [5]. Furthermore, the signature 
of the secreted cytokines and the molecules expressed 
on the cell surface (for example, OX40 ligand (OX40L) 
or ICOS-1 (inducible costimulator-1)) determine the 
type of T cell polarization, for example, Th 1, Th 2, Th 17, 
or Treg [8].
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DCs can be divided into several subsets, which display 
diﬀ erent characteristics and tissue distributions. Discuss-
ing all possible DC subsets is beyond the scope of this 
review, but currently two main types of DC are known: 
myeloid DCs (mDCs), and plasmacytoid DCs (pDCs) 
[9,10]. Th e number of DCs circulating in blood is 
relatively low; therefore, in vitro cultured DCs are often 
used in studies. Human mDCs are predominantly 
generated by culturing monocytes in the presence of 
granulocyte-macrophage colony-stimulating factor (GM-
CSF) and IL-4; these cytokines are also mainly used to 
generate mDCs from mouse bone marrow. pDCs were 
previously isolated from blood, but nowadays they can 
also be generated after culturing human monocytes or 
mouse bone marrow in the presence of Flt-3 ligand 
(Flt-3L). An important characteristic of mDCs in the 
context of SLE is their ability to take up apoptotic and 
necrotic cell material [9] and present this to T cells [11]. 
In contrast to mDCs, pDCs are unable to ingest 
uncomplexed apoptotic and necrotic material [9]. 
However, when apoptotic material is in complex with 
(auto)antibodies, pDCs ingest these complexes. pDCs 
can produce high amounts of type I IFN (mainly IFN-α) 
and were, therefore, originally referred to as the natural 
interferon-producing cells [12]. Interestingly, high levels 
of IFN-α are found in SLE patients, suggesting the 
involvement of pDCs in the pathogenesis of SLE [13].
Th e activation and maturation of DCs can be accom-
plished by numerous agents, such as microorganisms, 
immune complexes, various cells of the innate and 
adaptive immune system, dying cells, or material derived 
from dying cells [5,8,14]. In the case of microorganisms, 
pathogen-associated molecular patterns (PAMPs) are 
recognized by DCs via pathogen recognition receptors 
(PRRs). Th ese PRRs comprise Toll-like receptors (TLRs), 
C-type lectin receptors, the intracellular RIG-I-like 
receptors and NOD-like receptors, of which the TLRs 
have been studied in most detail [10,14]. However, TLRs 
are not solely stimulated by PAMPs, but also by endoge-
nous TLR ligands, which can be released from dying cells 
and are referred to as danger-associated molecular 
patterns (DAMPs). Expression of the PRRs varies 
between the DC types and subsets, and also diﬀ ers 
between species. With regard to TLRs, mDCs express 
most of the known TLRs, whereas pDCs predominantly 
express TLR7 and 9. Currently, the involvement of TLR 
triggering by DAMPs in auto-immune diseases, and SLE 
in particular, is an area of active research [14]. We will 
address this topic in more detail below.
Insuffi  cient clearance of apoptotic material in SLE
An increased load of apoptotic material has been related 
to the induction of SLE and the disease severity [3,4]. 
Th is increased load of apoptotic material can, in theory, 
result from aberrant apoptosis and/or insuﬃ  cient clear-
ance of apoptotic cells [15,16]. While some limited data 
support an increased rate of apoptosis in SLE in humans, 
animal models have shown that aberrant apoptosis, as in 
mice with defective Fas (lpr) or Fas ligand (gld), results in 
lymphoproliferation and autoimmunity with SLE-like 
features. Deregulated apoptosis ultimately leads to 
increased amounts of apoptotic cells at the wrong time or 
in a wrong micro-environment. However, an increasing 
body of evidence indicates that insuﬃ  cient clearance is 
probably a more important cause of the increased load of 
apoptotic material in SLE.
In contrast to the normal situation, where early 
apoptotic cells are swiftly removed by phagocytosis, 
insuﬃ  cient clearance of apoptotic cells and material may 
result in accumulation of these in tissues, and apoptosis 
can then proceed to secondary necrosis and to the release 
of inﬂ ammatory stimuli.
Apoptotic blebs, containing clustered autoantigens, 
are formed at the surface of the dying cell. As long as 
cells are not cleared, apoptosis continues and the 
formed blebs will separate from the apoptotic cell. We 
deﬁ ne an apoptotic cell body as an apoptotic cell that 
has ﬁ nished blebbing (Figure 1). In SLE patients, several 
abnormalities have been found that can result in 
decreased clearance of apoptotic cells and the release of 
blebs and chromatin, such as complement defects [17], 
low levels of the pentraxin C-reactive protein [18], and 
reduced levels and activity of DNase I in serum [19]. 
Th e association between factors involved in reduced 
apoptotic cell clear ance and SLE has also been found in 
animal models of SLE. In mice, the absence or decreased 
levels of comple ment component 1q (C1q), serum 
amyloid P component, DNase I, c-mer, or milk fat 
globule epidermal growth factor 8 results in lupus-like 
manifestations [16].
Figure 1. Scheme defi ning apoptotic blebs and apoptotic cell 
bodies. From left to right are a healthy cell, an actively blebbing 
apoptotic cell, and an apoptotic cell body (ACB), remaining after the 
cell has fi nished blebbing, with separated apoptotic blebs (blebs) 
[27].
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Insuffi  cient clearance of apoptotic material results 
in the release of modifi ed autoantigens that can 
illicit an immune response
Insuﬃ  cient clearance of apoptotic material does not 
directly provide an explanation for the pathogenesis of 
SLE, since tolerance towards self is not automatically 
aﬀ ected. Th e immune system is constantly in contact 
with numerous self-antigens, and it harbors multiple 
mechanisms to prevent autoimmunity [5,20,21]. Yet, one 
can imagine two pathways leading to an immune 
response against self-antigens. First, self is presented in 
an immunogenic context by antigen-presenting cells - for 
example, DCs - to auto-reactive T cells that have escaped 
central and peripheral tolerance mechanisms. Th e 
activated T cells provide the help needed for the subse-
quent activation of autoreactive B cells presenting the self 
epitopes. Second, modiﬁ ed or cryptic self is presented in 
an immunogenic context by DCs to T cells. When B cells 
ingest modiﬁ ed self that is recognized by their B cell 
receptor, they will present the peptides derived from this 
material. Th e activated T  cells recognizing modiﬁ ed 
peptides can provide the help necessary for the activation 
of these B cells, resulting in the production of antibodies 
directed towards modiﬁ ed self. Because the tolerance 
mechanisms for B cells are less stringent than those for 
T  cells, natural autoreactive B cells speciﬁ c for un-
modiﬁ ed parts of self-antigens are present. In SLE 
patients, this fraction of autoreactive B cells is probably 
even larger than in healthy individuals [22]. Since these B 
cells can present peptides derived from the modiﬁ ed as 
well as the unmodiﬁ ed parts of the ingested antigen, they 
can receive help from activated T  cells recognizing any 
one of these peptides. Th is mechanism of epitope 
spreading will ultimately result in the activation of 
various autoreactive T and B cells. We favor an important 
contribution of this second pathway, where the initial 
response is directed towards modiﬁ ed self, since it does 
not require the failure of physiological tolerance mecha-
nisms. Experimental evidence for the involvement of 
modiﬁ ed self is found in the speciﬁ city of autoantibodies 
that are found in SLE patients. Antibodies from these 
patients recognize self-antigens that are modiﬁ ed during 
the process of apoptosis. Th is is exempliﬁ ed in one of our 
own studies showing autoantibodies recognizing 
apoptosis-modiﬁ ed histone H4 [23].
Immunogenic presentation of (modifi ed) 
autoantigens by matured dendritic cells
mDCs are excellent phagocytes of apoptotic material and, 
after maturation, are the most potent antigen-present ing 
cells for the activation of (naïve) T cells [5,11]. Maturation 
of DCs can be induced by ligation of CD40 and by a 
diverse range of PAMPS, which are recognized by the 
DCs via TLRs and other PRRs. However, in addition to 
exogenous TLR ligands, more and more endogenous 
ligands, or DAMPs, have been identiﬁ ed [14,24]. When 
apoptotic cells are not swiftly removed, they release blebs 
and enter a late apoptotic stage, which is also called 
secondary necrosis. In this situation there is a huge spill 
of DAMPs, as in primary necrosis (Figure 2). As outlined 
below, there is evidence that these DAMPs, as well as 
apoptotic blebs and modiﬁ ed autoantigens, are able to 
induce maturation of DCs. When apoptotic T  cells are 
captured by DCs, the expression level of CD40 ligand 
(CD40L), which is increased by activating stimuli, aﬀ ects 
the maturation of DCs [25,26]. Furthermore, the level of 
maturation of DCs also depends on the amount of 
apoptotic material to which they are exposed [27,28]. Th e 
ﬁ nal common pathway of these mechanisms is that in 
conditions of disturbed apoptosis and/or insuﬃ  cient 
clearance, the apoptotic (modiﬁ ed) antigens will be 
presented in a more immunogenic way by DCs to T cells. 
A well known endogenous danger signal is the high-
mobility group box 1 protein (HMGB1), which can 
activate DCs via TLR2, TLR4 and the receptor for 
advanced glycation end products (RAGE) [29]. HMGB1 
was identiﬁ ed as the factor in HMGB1-nucleosome 
complexes from apoptotic cells that induced maturation 
of DCs via TLR2. In contrast to nucleosomes from 
normal cells, apoptotic nucleosomes induced auto anti-
body production in normal mice [30]. Other endogenous 
Figure 2. Immunogenic properties of the late apoptotic and 
necrotic cells. 1, Necrotic cells and late apoptotic/secondary necrotic 
cells spill maturing agents (M; such as HMGB1 and nucleosomes) 
into the environment, and consequently create infl ammatory 
conditions. 2, Under normal conditions, apoptotic cells do not spill 
maturing agents, but are removed effi  ciently by neighbouring cells 
and phagocytes, such as macrophages. 3, When the clearance of 
apoptotic cells is diminished and/or excessive apoptosis occurs, 
blebs are segregated from the apoptotic cell body and can induce 
maturation of dendritic cells (DC) upon ingestion. MΦ, macrophage.
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ligands for TLR2 and TLR4 are certain heat-shock 
proteins and heparan sulfate [14]. Nucleic acids are 
endogenous ligands for the endosomally located TLR3, 7, 
8, and 9. Double- and single-stranded RNA induce 
matura tion of DCs through TLR3 and TLR7/8, respec-
tively, while CpG containing double-stranded DNA is a 
ligand for TLR9. When DNA-containing chromatin is 
bound to autoantibodies, the immune complex can enter 
the endosome via Fc receptor-mediated uptake and thus 
activate DCs in a TLR9-dependent manner [31,32]. How-
ever, a TLR-9-independent activation of mDCs by 
chromatin-immunoglobulin complexes or nucleosomes 
has also been described [23,32,33]. We have shown that 
nucleosomes containing apoptotic histone modiﬁ cations 
are far more potent in inducing maturation of mouse 
mDCs than unmodiﬁ ed nucleosomes [23]. Notably, there 
can be an interaction between the various pathways of 
DC activation by endogenous ligands, since an essential 
role for HMGB1 and RAGE was demonstrated in TLR9-
dependent activation of plasmacytoid DCs and B cells 
[34]. It was recently discovered that DAMPs can also ligate 
CD24, which binds to Siglec G (mouse) or Siglec 10 
(human), and thereby repress the pro-inﬂ ammatory 
response [35]. Th is suggests that the response to DAMPs 
depends on the balance between positive and negative 
signaling pathways. In this respect it is interesting that a 
polymorphism in human CD24 is associated with 
susceptibility to autoimmune diseases, including SLE [36].
We recently found that apoptotic blebs can induce 
maturation of mouse mDCs with the production of high 
amounts of IL-6 [27]. Th is eﬀ ect was not observed with 
apoptotic cell bodies, the remainder of the dying cell after 
blebbing has ﬁ nished. Interestingly, many of the potential 
endogenous ligands that can activate DCs, including 
RNA, DNA, and HMGB1, are found in blebs [37,38]. In 
addition, HMGB1 remains attached to the nucleosomes 
that are released from late apoptotic cells [30]. Taken 
together, the disturbed clearance of apoptotic cells leads 
to an accumulation of blebs with immunogenic modiﬁ ca-
tion of autoantigens. Th e simultaneous presence of 
endoge nous danger signals and possibly a deﬁ ciency of 
regulatory pathways will enhance the ability of DCs to 
initiate an immune response to (modiﬁ ed) autoantigens.
Th e important role of DCs presenting apoptotic 
material in the pathogenesis of SLE is illustrated by 
studies showing that administration of mDCs loaded 
with apoptotic or necrotic cells can induce the formation 
of antinuclear antibodies in normal mice and in lupus 
mice [39,40]. Furthermore, vaccination with these DCs in 
lupus mice increased the disease severity [39-41].
Th e involvement of TLRs in the pathogenesis of SLE is 
supported by the observation that lupus-prone mice 
deﬁ cient in MyD88, a critical adaptor in most TLR 
signaling, did not develop autoimmune nephritis [42]. 
Accordingly, lupus-prone mice that are deﬁ cient in Sigirr, 
a negative regulator in TLR signaling, show accelerated 
disease progression [43]. In TLR9-deﬁ cient lupus-prone 
mice, the generation of anti-DNA and anti-chromatin 
autoantibodies was impaired [44], which was, however, 
dependent on the genetic background. Furthermore, a 
protective eﬀ ect of TLR9 signaling has also been des-
cribed in animal models [45]. In humans, an association 
between genetic variation in TLR9 and SLE susceptibility 
could not be demonstrated [46]. Th e involvement of 
TLR7 signaling in SLE pathogenesis is especially evident 
from mouse studies. Th e generation of autoantibodies 
recognizing RNA-containing antigens was shown to be 
TLR7 dependent [45]. Furthermore, the RNA component 
of the Sm/RNP (Smith antigen/small nuclear ribo nucleo-
proteins) and SS-A 60 lupus autoantigens contributes to 
DC maturation in vivo, probably via a TLR7- dependent 
pathway [47]. Overexpression of TLR7 caused profound 
DC dysregulation, increased levels of proinﬂ ammatory 
cytokines, such as IL-6 and TNF-α, in sera, SLE auto-
antibody production and fatal systemic autoimmu nity 
[48,49]. However, no evidence for increased TLR7 
expression was found in SLE patients [50]. When 
signaling via TLR3, TLR7, and TLR9 was abolished 
simul taneously in lupus-prone mice, the production of 
antinuclear antibodies and disease manifestation were 
markedly reduced [51]. As proposed by Baccala and 
colleagues [52], the dependency on TLR signaling may 
vary with the phase of SLE development. Th e initiation 
phase might concern TLR-independent maturation of 
DCs by apop totic material and associated nucleic acids. 
After the formation of autoantibodies an ampliﬁ cation 
phase can be initiated where Fc receptor-dependent 
uptake of nucleic-acid-containing immune complexes 
induces TLR-dependent maturation of DCs. Taken 
together, evidence for a role for TLRs in the pathogenesis 
of SLE is mainly derived from animal models, and the 
relevance in human lupus has still to be shown.
A Th17 polarizing eff ect of dendritic cells in SLE
As outlined above, the interaction between DCs loaded 
with antigens derived from apoptotic cells and naïve 
T  cells can give rise to various responses of sub popu-
lations of T cells. First, when immature DCs present self 
antigens in a tolerogenic way, autoreactive T  cells are 
deleted or anergized, and regulatory T  cells can be 
activated. Th e development of regulatory T  cells largely 
depends on the presence of TGF-β. When mature DCs 
present antigens in an immunogenic way, cytotoxic T cells 
as well as helper T cells can be activated. Helper T cells 
have traditionally been divided into type 1 (Th 1) and type 
2 (Th 2) subsets, and until recently many auto immune 
diseases were associated with a Th 1 type of autoimmune 
response [53]. However, recent data have clearly 
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demonstrated a crucial role for the IL-17 producing Th 17 
subset in autoimmune diseases [53]. For example, in 
contrast to the Th 1-promoting cytokine IL-12, the Th 17-
promoting cytokine IL-23 is involved in joint destruction 
in a rheumatoid arthritis model. Block ing IL-17 with a 
monoclonal antibody decreased intes tinal inﬂ ammation 
signiﬁ cantly in a mouse model for inﬂ ammatory bowel 
disease [53]. In mice, both Th 17 and Tregs require TGF-β 
for their development. However, in the presence of IL-6 
the development of Tregs is decreased, and their 
suppressive function is inhibited [54], whereas the 
combination of IL-6 and TGF-β is required for Th 17 
development [53]. Further more, IL-23 and IL-21 mediate 
the eﬃ  cient expansion of the Th 17 subset [53]. In humans, 
the development of Th 17 cells appears to be diﬀ erent from 
mice, although there is no consensus when comparing 
various studies. Several studies using human cells 
demonstrated that as well as IL-6 and TGF-β, Th 17 cell 
activation and diﬀ eren tiation can involve IL-1β, IL-21, 
and IL-23 [53]. Com pared to other autoimmune diseases, 
little is yet known about the role and involvement of Th 17 
cells in SLE. However, there are several indications that 
Th 17 cells and cytokines involved in activation and 
expansion of these cells are important. For instance, 
hyperproduction of IL-17 and IL-23 was observed in SLE 
patients [55]. Besides producing IFN-γ, expanded double 
negative T cells from SLE patients were found to produce 
signiﬁ cant amounts of IL-17. Th ese double negative 
IL-17-producing T cells were shown to inﬁ ltrate kidneys 
of lupus patients with nephritis [56]. In addition, increased 
numbers of Th 17 cells are associated with disease ﬂ ares of 
SLE. During these ﬂ ares the Treg population was 
contracted [57]. Lupus mice deﬁ cient in TNF receptor 1 
and 2 develop accelerated lupus via a Th 17-associated 
pathway [58]. Furthermore, IL-21 signaling was shown to 
be important in disease patho genesis in lupus-prone mice 
[59]. Eﬀ ective peptide tolerance therapy in lupus mice was 
associated with reduced numbers of Th 17 cells and 
expansion of Tregs. DCs from tolerized mice, especially 
pDCs, were altered and produced increased levels of 
TGF-β and decreased levels of IL-6 after stimulation with 
nucleosomes, a condition favoring the expansion of Tregs 
[60]. In conclusion, several lines of evidence support that 
Th 17 cells and related cytokines are important in the 
patho genesis of SLE.
As described above, mDCs that are co-cultured with 
nucleosomes, nucleosomes modiﬁ ed during apoptosis, or 
apoptotic blebs gain a mature phenotype and produce 
high concentrations of IL-6. In addition, we found that 
when mouse mDCs matured by apoptotic blebs are used 
as stimulator cells in an allogeneic mixed leukocyte 
reaction, they induce IL-17 production by responder 
splenocytes [27]. Th is suggests that the TGF-β-facilitated 
induction of Tregs under non-inﬂ ammatory conditions 
can be diverted to Th 17 activation and development 
when mDCs produce high levels of IL-6 after interaction 
with nucleosomes or blebs released from apoptotic cells.
Conclusion
Th e etiology of SLE is multifactorial, with evidence for 
the involvement of genetic predisposition, certain 
pathogens, a decreased lymphocyte responsiveness to 
Treg suppression, gender-dependent diﬀ erences in T cell 
activation, alterations in the complement system, an 
enlarged naïve, mature autoreactive B-lymphocyte pool 
[22], and aberrant apoptosis and/or insuﬃ  cient clearance 
of apoptotic cells [3,4]. Based on our current knowledge, 
we propose the following model, which is graphically 
depicted in Figure  3. Due to aberrant apoptosis, and/or 
insuﬃ  cient clearance of apoptotic cells, combined with a 
SLE-susceptible genetic background, high (local or 
systemic) concentrations of apoptotic nucleosomes and 
blebs are present in SLE patients. Th ese apoptotic nucleo-
somes and blebs can then be ingested by mDCs. Nucleo-
somes that are modiﬁ ed during apoptosis, and/or 
endogenous danger ligands incorporated in blebs are 
responsible for the maturation of mDCs, which 
subsequently secrete proinﬂ ammatory cytokines such as 
IL-6, and present apoptosis-induced, modiﬁ ed auto anti-
gens in an immunogenic way to T cells. Th e development 
and activity of Tregs is inhibited by IL-6, whereas IL-6 
may, in combination with TGF-β and/or other pro inﬂ am-
matory cytokines, lead to the activation of Th 17 cells and 
other Th  cell subsets. Although the initially activated Th  
cells may be speciﬁ c for modiﬁ ed autoantigens, epitope 
spreading will account for activation of B cells speciﬁ c for 
modiﬁ ed as well as unmodiﬁ ed autoantigens. Th e pro-
duced autoantibodies will form immune complexes with 
antigens released from improperly cleared apoptotic 
cells. Th e opsonization of apoptotic material by auto anti-
bodies enhances its uptake by mDCs [61]. Moreover, 
pDCs encountering these immune complexes produce 
high concentrations of IFN-α [62], which adds to the 
maturation of mDCs and supports isotype switching and 
autoantibody production by autoreactive B cells [63]. In 
this way, pDCs can amplify the autoimmune response 
initiated by mDCs. Moreover, the immune complexes 
can bind to basement membranes in diverse organs, 
causing inﬂ ammation, which leads to the various disease 
manifestations, including lupus nephritis, and tissue 
destruction [64]. In turn, the tissue destruction can result 
in a local increase in apoptosis, yet another positive 
feedback loop that contributes to a progressive course of 
the disease in time.
Based on this model we postulate that DCs play a 
pivotal role in the initiation and progression of SLE. 
Although SLE patients are often treated with rather 
unspeciﬁ c immunosuppressive drugs, the data presented 
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here suggest that speciﬁ c interference in the maturation 
of DCs, TLR signaling, or the development of certain 
T  cell subsets might become attractive treatment goals. 
For example, hydroxychloroquine, which inhibits signal-
ing via TLR3, 7, 8 and 9 by blocking the acidiﬁ cation of 
endosomes, is a well known eﬀ ective drug in the treat-
ment of SLE patients [65]. Furthermore, inhibition of 
TLR7 and 9 was recently shown to ameliorate the disease 
manifestations in lupus-prone mice [66]. Further know-
ledge of the role of endogenous apoptotic (modiﬁ ed) 
compounds and their receptors in the maturation of DCs 
and the activation of speciﬁ c T cell subsets, such as Th 17 
cells, may reveal novel targets for the speciﬁ c treatment 
of SLE.
Figure 3. Model for the development of systemic lupus erythematosus and its infl ammatory manifestations. In systemic lupus 
erythematosus (SLE), aberrant apoptosis or insuffi  cient clearance of apoptotic cells leads to the local or systemic presence of high amounts of 
apoptotic blebs and nucleosomes, which are modifi ed during apoptosis. These are then taken up by immature myeloid dendritic cells (mDCs). 
After ingestion of apoptotic blebs or nucleosomes, mDCs gain a mature phenotype with increased expression of costimulatory molecules (for 
example, CD40 and CD86), and production of proinfl ammatory cytokines, such as IL-6. Mature mDCs can induce activation of Th1 or Th2 cells 
and, in the presence of TGF-β, IL-6 and/or other proinfl ammatory cytokines, also support the development of Th17 cells. Next to its role in Th17 
development, IL-6 inhibits the development and activity of regulatory T cells (Tregs). After activation by T helper (Th) cells, autoreactive B cells 
produce autoantibodies, which can form immune complexes with apoptotic material. Plasmacytoid dendritic cells (pDCs) preferentially take up 
these immune complexes and subsequently produce high amounts of IFN-α, which enhances autoantibody production and isotype switching. This 
results in increasing concentrations of immune complexes, which can associate with the (glomerular) basement membrane. The resulting infl ux 
of immune cells ultimately gives rise to multiple disease manifestations, including lupus nephritis, and local tissue damage, thereby inducing an 
increase in apoptotic cells, which ‘feeds’ mDCs with immunogenic material. ACB, apoptotic cell body (“late apoptotic cell”); Blebs, apoptotic blebs; 
EAC, early apoptotic cell; MΦ, macrophage; mDC, myeloid dendritic cell; Nucleosomes, apoptosis-induced hyper acetylated nucleosomes; pDC, 
plasmacytoid dendritic cell; Th, T helper cell; Treg, regulatory T cell.
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